Clinical Trial Update: Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E [Phase 4]

View source ↗

Summary

This clinical trial update reports results from a Phase 4 study evaluating Brolocizumab with immediate Treat-and-Extend dosing for recalcitrant neovascular age-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Brolocizumab

Snippet

Sponsor: The University of Hong Kong | Conditions: Age-Related Macular Degeneration | Phase 4 | Status: COMPLETED